We are live on
!
Find out more
GIM
Granahan Investment Management Portfolio holdings
AUM
$2.07B
1-Year Est. Return
56.45%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+56.45%
3 Year Est. Return
+154.74%
5 Year Est. Return
+144.99%
10 Year Est. Return
+2,522.93%
AUM
$1.86B
AUM Growth
-$316M
(-15%)
Cap. Flow
+$201M
Cap. Flow
% of AUM
10.84%
Top 10 Holdings %
Top 10 Hldgs %
33.97%
Holding
201
New
20
Increased
89
Reduced
75
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Trade Desk
TTD
|
+$28.3M |
| 2 |
AXON
Axon Enterprise
AXON
|
+$25.9M |
| 3 |
Bright Horizons
BFAM
|
+$22.8M |
| 4 |
LivePerson
LPSN
|
+$22.6M |
| 5 |
Magnite
MGNI
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CoStar Group
CSGP
|
+$24M |
| 2 |
Enphase Energy
ENPH
|
+$23.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$23.4M |
| 4 |
eHealth
EHTH
|
+$22.6M |
| 5 |
Teladoc Health
TDOC
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.7% |
| 2 | Healthcare | 18.21% |
| 3 | Industrials | 12.95% |
| 4 | Consumer Staples | 7.14% |
| 5 | Consumer Discretionary | 6.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
CRISPR Therapeutics
CRSP
$5.23B
| $1.45M | 0.08% |
34,127
-455
| -1% | -$23.5K |
|
|
CDTX
152
DELISTED
Cidara Therapeutics
CDTX
| $1.43M | 0.08% |
28,765
+5,259
| +22% | +$315K |
|
|
IOTS
153
DELISTED
Adesto Technologies Corp
IOTS
| $1.41M | 0.08% |
126,144
-817,507
| -87% | -$7.81M |
|
154
Spero Therapeutics
SPRO
$71.2M
| $1.39M | 0.07% |
171,434
+22,567
| +15% | +$199K |
|
155
MacroGenics
MGNX
$250M
| $1.31M | 0.07% |
224,638
-1,313
| -0.6% | -$11.9K |
|
156
Xenon Pharmaceuticals
XENE
$6.09B
| $1.26M | 0.07% |
110,999
+4,160
| +4% | +$59.2K |
|
157
Vail Resorts
MTN
$5.28B
| $1.25M | 0.07% |
+8,495
| New | +$1.83M |
|
|
JNCE
158
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.25M | 0.07% |
264,139
+141,857
| +116% | +$817K |
|
|
SHSP
159
DELISTED
SharpSpring, Inc.
SHSP
| $1.22M | 0.07% |
201,949
+92,073
| +84% | +$990K |
|
160
Castle Biosciences
CSTL
$999M
| $1.21M | 0.07% |
40,730
-12,133
| -23% | -$366K |
|
161
Collegium Pharmaceutical
COLL
$854M
| $1.21M | 0.07% |
74,047
+57,860
| +357% | +$1.19M |
|
162
Varonis Systems
VRNS
$4.84B
| $1.1M | 0.06% |
51,621
+17,775
| +53% | +$466K |
|
163
Editas Medicine
EDIT
$455M
| $1.08M | 0.06% |
54,537
-808
| -1% | -$20.4K |
|
|
PFIE
164
DELISTED
Profire Energy, Inc
PFIE
| $1.08M | 0.06% |
1,369,471
-34,260
| -2% | -$41.8K |
|
165
Datadog
DDOG
$89.2B
| $1.01M | 0.05% |
28,019
+8,555
| +44% | +$353K |
|
166
Organogenesis Holdings
ORGO
$242M
| $924K | 0.05% |
285,990
+35,990
| +14% | +$154K |
|
|
AKTS
167
DELISTED
Akoustis Technologies Inc
AKTS
| $824K | 0.04% |
153,363
+57,325
| +60% | +$402K |
|
168
Intellia Therapeutics
NTLA
$1.66B
| $726K | 0.04% |
59,342
-765
| -1% | -$10.3K |
|
|
ITRM
169
DELISTED
Iterum Therapeutics
ITRM
| $653K | 0.04% |
16,075
-223
| -1% | -$9.38K |
|
|
SGMO
170
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $644K | 0.03% |
101,098
-1,537
| -1% | -$11.4K |
|
171
WIX.com
WIX
$2.82B
| $592K | 0.03% |
+5,874
| New | +$767K |
|
|
SOHO
172
DELISTED
Sotherly Hotels
SOHO
| $563K | 0.03% |
351,569
-289
| -0.1% | -$1.44K |
|
173
Western Digital
WDC
$152B
| $559K | 0.03% |
+17,777
| New | +$787K |
|
174
Plug Power
PLUG
$3.11B
| $488K | 0.03% |
+137,749
| New | +$561K |
|
175
Match Group
MTCH
$8.46B
| $440K | 0.02% |
6,659
-5,012
| -43% | -$368K |
|
Similar funds
BC
AG
TA
ACP
TP
NSUP
ACG
CL
Granahan Investment Management's Q1 2020 Portfolio in Review
As of Q1 2020, Granahan Investment Management held 201 positions worth $1.86B, down 15% from $2.17B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Granahan Investment Management deployed $201M of net new capital in Q1 2020, opening 20 new positions and adding to 89 existing holdings. Its largest new stake was Trade Desk: 1,094,660 shares worth $21.1M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was CoStar Group, an estimated $24M trimmed.
- Granahan Investment Management's largest Q1 2020 buy was Trade Desk: 1,094,660 shares worth $21.1M.
- Granahan Investment Management added most to Axon Enterprise in Q1 2020, an estimated $25.9M increase.
- Granahan Investment Management's biggest Q1 2020 reduction was CoStar Group, cutting an estimated $24M.
- Granahan Investment Management fully exited Medicines Co in Q1 2020, selling an estimated $23.4M.
- Granahan Investment Management's ten largest holdings make up 34% of its $1.86B portfolio in Q1 2020.
- Granahan Investment Management opened 20 new positions and closed 17 in Q1 2020.
- Granahan Investment Management's portfolio value fell 15% quarter-over-quarter to $1.86B.
Based on Granahan Investment Management's 13F filing for Q1 2020, filed 12 May 2020.